123 related articles for article (PubMed ID: 32781041)
21. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
[TBL] [Abstract][Full Text] [Related]
22. Reconsideration of progression to CRPC during androgen deprivation therapy.
Mizokami A; Namiki M
J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975
[TBL] [Abstract][Full Text] [Related]
23. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
[TBL] [Abstract][Full Text] [Related]
24. How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2021 Oct; 19(10):627-630. PubMed ID: 34637427
[No Abstract] [Full Text] [Related]
25. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
[TBL] [Abstract][Full Text] [Related]
26. The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.
Moul JW
Oncology (Williston Park); 2014 Aug; 28(8):702-3, 722. PubMed ID: 25140628
[No Abstract] [Full Text] [Related]
27. Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment.
Cheng B; Huang H
Cancer Biol Med; 2023 Aug; 20(8):568-74. PubMed ID: 37646236
[No Abstract] [Full Text] [Related]
28. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.
Imamura Y; Sadar MD
Int J Urol; 2016 Aug; 23(8):654-65. PubMed ID: 27302572
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
Singh KB; Ji X; Singh SV
Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
32. Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer.
Nagireddy S; Qureshi R; Best J; Frech FS; Shah K; Soni Y; Kuchakulla M; Narasimman M; Arora H
Adv Exp Med Biol; 2021; 1329():295-323. PubMed ID: 34664246
[TBL] [Abstract][Full Text] [Related]
33. [Castration resistance mechanisms in prostate cancer.].
Martínez-Breijo S; Chantada-Abal V; Aller-Rodríguez M; Bohórquez-Cruz M; Sacristán-Lista F; Ponce-Díaz J; Vázquez-Martul D; Lamas-Díaz L
Arch Esp Urol; 2018 Sep; 71(8):628-638. PubMed ID: 30319123
[TBL] [Abstract][Full Text] [Related]
34. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
35. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
36. Sequencing strategies in the new treatment landscape of prostate cancer.
Caffo O; Maines F; Kinspergher S; Veccia A; Messina C
Future Oncol; 2019 Sep; 15(25):2967-2982. PubMed ID: 31424285
[TBL] [Abstract][Full Text] [Related]
37. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance.
Cai Z; Wu Y; Li Y; Ren J; Wang L
Aging (Albany NY); 2018 Dec; 10(12):3702-3712. PubMed ID: 30513511
[TBL] [Abstract][Full Text] [Related]
38. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
Fujimoto N
J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
[TBL] [Abstract][Full Text] [Related]
39. Can progressive site-directed therapy prolong the efficacy of subsequent androgen receptor axis-targeted drugs in oligometastatic castration-resistant prostate cancer?
Yoshida S; Takahara T; Yokoyama M; Matsuoka Y; Yoshimura R; Fujii Y
Int J Urol; 2021 Feb; 28(2):241-242. PubMed ID: 33140442
[No Abstract] [Full Text] [Related]
40. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
Bryce AH; Antonarakis ES
Int J Urol; 2016 Aug; 23(8):646-53. PubMed ID: 27255944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
